About Aldevron
Aldevron is a Healthcare company based in Fargo (United States) founded in 1998, and was acquired by Danaher in June 2021. Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications. The company has 747 employees. Aldevron has completed 1 acquisition, including Genovac. Its website aldevron.com draws about 13 thousand monthly visits. Aldevron offers products and services including Plasmid DNA Manufacturing, mRNA Manufacturing, and Protein and Enzyme Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Life Sciences. Its legal entity is ALDEVRON, LLC. Its competitors include Senti Biosciences, Poseida Therapeutics and KBI Biopharma; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 1998 and based in Fargo, United States, Aldevron operates in the biotechnology sector, focusing on nucleic acid and protein manufacturing. Plasmid DNA production has been completed for over 70,000 projects using proprietary methods, supporting research, preclinical, clinical, and diagnostic needs. Services include gene-to-protein manufacturing for custom enzymes, recombinant antibodies, and proteins, alongside antibody development through genetic, protein, and peptide immunization for reagents, diagnostics, and therapeutics.
- Headquarters Fargo, United States
- Employees 747
- Stage Acquired
- SectorsHealthcare
- Website aldevron.com
- Social LinkedIn X Facebook
- Acquired by Danaher (Jun 2021)
- Legal Name Aldevron, Llc
Products & Services of Aldevron
Aldevron offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, mRNA Manufacturing, and Protein and Enzyme Manufacturing.
Produces high-quality DNA for research and clinical applications.
Offers scalable RNA production with encapsulation options.
Creates custom proteins for diagnostics and therapy uses.
Funding Insights of Aldevron
- Total Rounds 4
- First Round $1.1M
(Aug 2007)
- Investors Count 2
All 4 funding rounds of Aldevron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
4 investors in total: 4 institutional.
Investors in Aldevron
Aldevron has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Danaher, EQT and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by private equity firm TA. | ta.com | Boston, United States | ||
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Dental equipment and medical instruments are manufactured for therapeutic areas. | 1969 | danaher.com |
Investor details for Aldevron
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aldevron
4 people are tracked at Aldevron (2 in leadership, 2 in team); the tracked headcount is 747.
| Name | Role | Group |
|---|---|---|
Rachel Lei | Vice President And General Counsel | Leadership |
Michael Chambers | Founding Ceo, Executive Chairman | Leadership |
Keleigh Pearson | Assistant General Counsel - NABU | Team |
Jessica L. | Associate General Counsel | Team |
Complete people profiles for Aldevron
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aldevron
Aldevron has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genovac.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody discovery platforms and technologies are developed for protein targets. | genovac.com | Fargo, United States | 1999 | Apr 2004 | •••• |
Complete acquisition details for Aldevron
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aldevron
6 dated milestones of Aldevron across 23 years, from founding to its latest funding, stage changes and deals.
Competitors of Aldevron
Aldevron has 3 listed competitors in our database, 3 of them funded. They include Senti Biosciences, Poseida Therapeutics and KBI Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. | ||
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| kbibiopharma.com | 1996 | Durham, United States | $17M | 1,243 | Provider of protein formulation, process & cell line development, and cGMP services |
Detailed competitors of Aldevron
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aldevron
The website of Aldevron (aldevron.com) receives about 12.5K visits a month.
- Monthly visits12.5K
▼ 31.6% vs previous month
Websites whose visitors overlap most with Aldevron. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellbiolabs.com | 100% | 38.9K | #876,566 | View details | |
promega.de | promega.de | 95% | #537,695 | – | |
| olink.com | 89% | 59.4K | #589,604 | View details | |
bacmap.wishartlab.com | bacmap.wishartlab.com | 89% | – | ||
| cusabio.com | 89% | #252,380 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Aldevron
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Aldevron (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aldevron
Complete news archive for Aldevron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aldevron
Aldevron was founded in 1998 and raised its 1st funding round 9 years after it was founded.
Aldevron is headquartered in Fargo, United States. It is registered at Fargo, North Dakota, United States.
Aldevron has 747 employees.
Founded in 1998 and based in Fargo, United States, Aldevron operates in the biotechnology sector, focusing on nucleic acid and protein manufacturing. Plasmid DNA production has been completed for over 70,000 projects using proprietary methods, supporting research, preclinical, clinical, and diagnostic needs. Services include gene-to-protein manufacturing for custom enzymes, recombinant antibodies, and proteins, alongside antibody development through genetic, protein, and peptide immunization for reagents, diagnostics, and therapeutics.
Aldevron's top competitors include Senti Biosciences, KBI Biopharma and Poseida Therapeutics.
Aldevron offers Plasmid DNA Manufacturing, mRNA Manufacturing, and Protein and Enzyme Manufacturing.
Aldevron has made 1 acquisition, including Genovac.
Aldevron has 4 investors. Key investors include Danaher, EQT, HHS, and TA Associates.
Aldevron operates through Aldevron, Llc.
Yes. Aldevron was acquired by Danaher in June 2021.